LOGIN  |  REGISTER
C4 Therapeutics
Chimerix

TruBridge to Participate in Stephens 2024 Annual Investment Conference

November 12, 2024 | Last Trade: US$20.82 0.14 -0.67

MOBILE, Ala. / Nov 12, 2024 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that management will participate in the Stephens 2024 Annual Investment Conference to be held November 19-21, 2024, in Nashville, Tennessee.

The fireside chat presentation by Chris Fowler, president and chief executive officer, and Vinay Bassi, chief financial officer, will begin at approximately 2:00 p.m. Central Time on Wednesday, November 20, 2024, and will be available to investors via a live audio webcast. A link to the webcast can be found at the investor relations section of the Company’s website www.trubridge.com.

About TruBridge

We are a trusted partner to more than 1,500 healthcare organizations with a broad range of technology-first solutions that address the unique needs and challenges of diverse communities, promoting equitable access to quality care and fostering positive outcomes. TruBridge has over four decades of experience in connecting providers, patients and communities with innovative data-driven solutions that create real value by supporting both the financial and clinical side of healthcare delivery. Our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings combine unparalleled visibility and transparency to enhance productivity and support the financial health of healthcare organizations across all care settings. We support efficient patient care with electronic health record (EHR) product offerings that successfully integrate data between care settings. Above all, we believe in the power of community and encourage collaboration, connection, and empowerment with our customers. We clear the way for care. For more information, please visit www.trubridge.com.

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page